NewAmsterdam Pharma Company NV (NASDAQ: NAMS) is -29.14% lower on its value in year-to-date trading and has touched a low of $15.19 and a high of $27.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NAMS stock was last observed hovering at around $18.38 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $18.21, the stock is -19.71% and -15.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing -0.92% at the moment leaves the stock -9.50% off its SMA200. NAMS registered -14.79% loss for a year compared to 6-month gain of 9.70%. The firm has a 50-day simple moving average (SMA 50) of $21.4618 and a 200-day simple moving average (SMA200) of $20.120575.
The stock witnessed a -15.30% loss in the last 1 month and extending the period to 3 months gives it a -28.87%, and is -19.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.54% over the week and 6.16% over the month.
NewAmsterdam Pharma Company NV (NAMS) has around 68 employees, a market worth around $2.00B and $45.56M in sales. Profit margin for the company is -530.25%. Distance from 52-week low is 19.88% and -33.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.89%).
The EPS is expected to grow by 29.96% this year
179.0 institutions hold shares in NewAmsterdam Pharma Company NV (NAMS), with institutional investors hold 99.74% of the company’s shares. The shares outstanding are 108.06M, and float is at 57.95M with Short Float at 7.49%. Institutions hold 99.39% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 12.23 million shares valued at $234.88 million. The investor’s holdings represent 12.9097 of the NAMS Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 11.83 million shares valued at $227.28 million to account for 12.4921 of the shares outstanding. The other top investors are BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC which holds 10.47 million shares representing 11.0587 and valued at over $201.2 million, while RA CAPITAL MANAGEMENT, L.P. holds 8.5143 of the shares totaling 8.06 million with a market value of $154.91 million.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
The most recent transaction is an insider purchase by Topper James N, the company’s Director. SEC filings show that Topper James N bought 1,135 shares of the company’s common stock on Mar 26 ’25 at a price of $22.49 per share for a total of $25521.0. Following the purchase, the insider now owns 3.01 million shares.
Still, SEC filings show that on Mar 26 ’25, Douglas F Kling (Affiliate) Proposed Sale 16,539 shares at an average price of $23.41 for $0.39 million. The insider now directly holds shares of NewAmsterdam Pharma Company NV (NAMS).
